This gene-based therapeutics stock could nearly triple, analysts say
Three firms initiated coverage of the the gene-based therapeutics company.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
More in Finance & Markets
Australian Dollar remains resilient near two-month high ahead of Fed Minutes
AUD/USD edges higher on Tuesday and trades around 0.7115 at the time of writing, up 0.1% on the day.
U.S. investors have been buying stocks all month and are now sitting on profits. Here’s what might make them sell.
Given that investors are sitting on unrealized gains and there few short positions remain open, the markets are more vulnerable to a downturn in economic news flow.
U.S. investors have been buying stocks all month and are now sitting on profits. Here’s what might make them sell.
Given that investors are sitting on unrealized gains and there few short positions remain open, the markets are more vulnerable to a downturn in economic news flow.
Government to crack down on super switching schemes
Unlicensed telemarketers that cold call and make unsolicited approaches to consumers to convince them to switch their super will be banned under long-awaited reforms.
Nvidia Is on Track to Beat the S&P 500 for the 4th Straight Year. Should Its $500 Billion AI Infrastructure Financing Plan Give Investors Pause?
The chipmaker's partnership with six financial institutions will help diversify its customer base beyond hyperscalers and neoclouds.
Kalshi seeks to launch ‘perps’ on equity indexes as it moves in on traditional exchanges' turf
The company is seeking to launch a "US500" perp tied to the MerQube U.S. Large Cap Index, according to a regulatory filing.